Abstract 3492
Background
Soft tissue sarcomas (STS) form a group of rare cancers which accounts for around 1% of tumours. Although up to 15% of patients respond in immunotherapy trials, there are no biomarkers predicting response of STS to checkpoint blockade therapies yet.
Methods
We analysed transcriptomic data of 4 publicly available cohorts, accounting for more than 600 STS. We used MCP-counter, a deconvolution method to estimate the tumour microenvironment (TME) composition Based on MCP-counter estimates, we established a robust immune classificationof STS tumors into 5 Sarcoma Immune Classes, labelled A, B, C, D and E. These classes exhibited different type and extents of TME. We validated the profiles of these 5 groups on a 72-patients cohort using immunohistochemichal (IHC) stainings for CD3, CD8, CD20 and CD34.
Results
One group (A: 23.3% of tumours) exhibits a very low to low immune infiltrate for all TME cell types. Another class (C: 14.5% of all tumours) displays moderate immune infiltrate and a strong presence of endothelial cells. Finally, another group (E: 15.6%) is highly infiltrated by all immune cell types. The two remaining groups (B: 27.4% and D: 19.4%) are heterogeneous, respectively rather highly and lowly infiltrated. The immune high group E is associated with an overexpression of several immune checkpoint genes: PDCD1 (PD-1), CD274 (PD-L1), PDCD1LG2 (PD-L2), LAG3, HAVCR2 (TIM-3), CTLA4. On 72 patients, we showed that the immune-high group could be identified by the IHC-visible presence of tertiary lymphoid structures (TLS), defined as T cell aggregates juxtaposing B cell aggregates. The immune-high group also exhibited prolonged overall survival as compared with other groups. Using data from a phase II clinical trial with pembrolizumab, we show that responders can be identified as class E tumours, therefore allowing patient selection.
Conclusions
We have defined a novel immune-based classification of STS into 5 classes, among which an immune-high group characterized by a strong infiltration by all immune cell and expression of immune checkpoints, presence of TLS and longer overall survival. This class groups responders to PD-1 blockade in a phase II clinical trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
INSERM.
Funding
Institut National de la Santé et de la Recherche Médicale, the University of Paris, Sorbonne University, the Programme Cartes d’Identité des Tumeurs (CIT) from the Ligue Nationale Contre le Cancer, Institut National du Cancer (HTE-INSERM plan cancer, C16082DS), Association pour la Recherche sur le Cancer (ARC), Cancer Research for Personalized Medecine programme, “FONCER contre le cancer” programme, Labex Immuno-Oncology, the National Institute of Health, Moon Shot program at MD Anderson Cancer Center, Ministry of Education and Ministry of Science and Technology of Taiwan, National Taiwan University, Merck, Inc, SARC, Sarcoma Foundation of America, and the QuadW Foundation.
Disclosure
T.W. Chen: Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy: Lilly. M.A. Burgess: Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Immune Design; Advisory / Consultancy: Eisai. J. Wargo: Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Genentech; Advisory / Consultancy: Illumina. H.A. Tawbi: Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): Genentech; Research grant / Funding (self): Celgene; Research grant / Funding (self): GSK. W.H. Fridman: Advisory / Consultancy: MedImmune; Advisory / Consultancy: Novartis; Advisory / Consultancy: Servier; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2818 - Improved survival with secondary surgery in a reference center after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: an analysis 10931 patients (pts) in NETSARC.
Presenter: Francois Gouin
Session: Poster Discussion – Sarcoma
Resources:
Abstract
5826 - Impact of abstention of diagnostic biopsy in sarcoma
Presenter: Armelle Dufresne
Session: Poster Discussion – Sarcoma
Resources:
Abstract
4087 - EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma
Presenter: Peter Reichardt
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1363 - Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
Presenter: Javier Martin Broto
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1399 - Phase 1 combination dose-finding/phase 2 expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to _25 years with relapsed/refractory (r/r) osteosarcoma
Presenter: Nathalie Gaspar
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1884 - A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Presenter: Angela Hirbe
Session: Poster Discussion – Sarcoma
Resources:
Abstract
3452 - Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS)
Presenter: Maud Toulmonde
Session: Poster Discussion – Sarcoma
Resources:
Abstract
Poster Discussion – Sarcoma - Invited Discussant 1672PD, 1673PD and 1675PD
Presenter: Andrew Hayes
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast
Poster Discussion – Sarcoma - Invited Discussant 1674PD, 1676PD and 1677PD
Presenter: Emanuela Palmerini
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast
Poster Discussion – Sarcoma - Invited Discussant 1678PD and 1679PD
Presenter: Hans-Ulrich Schildhaus
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast